Lancet Sub-Journal (IF=54) Reduces Risk of Death by 42%! Fudan University Ye Dingwei's team first launched the "Chinese plan" for the treatment of metastatic hormone-sensitive prostate cancer

Prostate cancer is a malignant tumor with a very high incidence, ranking second in the world in the incidence of malignant tumors in men, after lung cancer

On September 5, 2022, Ye Dingwei's team from the Department of Urology of the Affiliated Cancer Hospital of Fudan University published an online article in Lancet Oncology magazine entitled "Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial" research paper, which lasted more than 4 years, compared the efficacy and safety of "reviruter combined castration therapy" and the classic "bicalutamide combined castration therapy" in patients with high tumor burden metastatic hormone-sensitive prostate cancer, It was confirmed that the first new second-generation antiandrogen drug "Revirutamine" combined with androgen deprivation therapy (castration therapy) independently developed by China was compared with the classic treatment plan, which can reduce the risk of death of patients with metastatic hormone-sensitive prostate cancer by 42% and the risk of imaging progression by 56%!

—END—

The content is [iNature]